MPM BioImpact’s Immatics IMTX Stock Holding History

MPM BioImpact’s Portfolio IMTX Stock Details IMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-417,810	Closed	-$4.85M	–	50
2024 Q2	$4.85M	Buy	417,810 +22,573	+6%	+$254K	0.75%	41
2024 Q1	$4.15M	Buy	+395,237	New	+$4.61M	0.67%	37

Other funds holding IMTX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

MPM BioImpact's IMTX Position: Q3 2024 in Review

MPM BioImpact sold out of Immatics (IMTX) in Q3 2024, closing a stake of 417,810 shares — an estimated $4.85M sold.

MPM BioImpact first reported a position in IMTX in Q1 2024 and held it in 2 quarters. The position peaked at $4.85M in Q2 2024. 91 funds tracked by Wall St. Rank hold IMTX as of Q3 2024.

MPM BioImpact reported no remaining Immatics position as of Q3 2024 after selling out during the quarter.
MPM BioImpact sold 417,810 Immatics shares in Q3 2024, an estimated $4.85M.
MPM BioImpact first reported a position in Immatics in Q1 2024 and held it in 2 quarters.
MPM BioImpact's Immatics position peaked at $4.85M in Q2 2024.
91 funds tracked by Wall St. Rank held Immatics as of Q3 2024.

Based on MPM BioImpact's 13F filing for Q3 2024, filed 13 Nov 2024.